Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30174292 | 1.00 | KCNH2 (0.45) | KCNH2GRM5MEN1KMT2AANO1 | |
| SCHEMBL25528964 | 0.87 | TSHR (0.52) | KCNH2GRM5MEN1KMT2AANO1 | |
| SCHEMBL30174284 | 0.87 | TSHR (0.52) | KCNH2GRM5MEN1KMT2AANO1 | |
| SCHEMBL19308461 | 0.84 | MEN1 (0.50) | KCNH2GRM5MEN1KMT2AANO1 | |
| SCHEMBL25235088 | 0.83 | SMARCA2 (0.54) | KCNH2MEN1KMT2A | |
| SCHEMBL18626344 | 0.83 | TSHR (0.54) | KCNH2GRM5MEN1KMT2AL3MBTL1 | |
| SCHEMBL25528970 | 0.82 | SORT1 (0.48) | MEN1KMT2A | |
| SCHEMBL30174182 | 0.82 | SORT1 (0.48) | MEN1KMT2A | |
| SCHEMBL19308446 | 0.80 | TP53 (0.51) | MEN1KMT2APTPRC | |
| SCHEMBL16305244 | 0.77 | KDM4E (0.47) | GRM5MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115605478-A | Compounds and methods of use | 埃克塞里艾克西斯公司（US） | 2023-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | KCNH2 3788/4885GRM5 1243/4885MEN1 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.